Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial [PDF]
Dermatology and Therapy, 2023 Introduction Hidradenitis suppurativa (HS) is a chronic, immune-mediated skin condition characterized by inflammatory lesions that can cause pain, impaired physical activity, and reduced quality of life.
, Errol Prens, Ziqian Geng
exaly +4 more sources
Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database [PDF]
Pharmaceutics, 2023 Risankizumab is a selective, humanized immunoglobulin G1 (IgG1) monoclonal anti-body directed against interleukin (IL)-23 protein. The therapeutic indication of risankizumab is moderate-to-severe plaque psoriasis and psoriatic arthritis.
Gioacchino Calapai +2 more
exaly +4 more sources
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis [PDF]
Drug Design, Development and Therapy, 2018 Isabel M Haugh,1 Allie K Preston,2 Dario N Kivelevitch,1 Alan M Menter1 1Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA; 2Texas A&M Health Science Center College of Medicine, Bryan, TX, USA Abstract: Risankizumab, a ...
Allie Preston +2 more
exaly +3 more sources
A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment [PDF]
Journal of Immunology Research, 2022 Biological targeted therapy serves as a new alternative treatment for psoriasis due to its minimal side effects. This study is aimed at examining the drug effectiveness and safety of risankizumab and ustekinumab for psoriasis treatment, so as to provide ...
Qianying Yu +7 more
doaj +2 more sources
Risankizumab: Mechanism of action, clinical and translational science [PDF]
Clinical and Translational ScienceRisankizumab is a high‐affinity neutralizing anti‐interleukin (IL)‐23 monoclonal antibody marketed in over 40 countries across the globe to treat several inflammatory diseases, such as plaque psoriasis (PsO), psoriatic arthritis (PsA), and Crohn's ...
Yinuo Pang +5 more
doaj +2 more sources
Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children [PDF]
Dermatology and Therapy, 2023 Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages, including children. PRP is characterized by follicular and palmoplantar hyperkeratosis and salmon-colored scaling plaques.
Marta Kołt-Kamińska +3 more
doaj +2 more sources
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials [PDF]
Rheumatology and TherapyIntroduction The ongoing KEEPsAKE 1 and 2 (KS1; KS2) trials evaluate the efficacy and safety of risankizumab in patients with psoriatic arthritis (PsA) who had an inadequate response to ≥ 1 conventional synthetic disease-modifying antirheumatic drug(s ...
Andrew Östör +15 more
doaj +2 more sources
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial [PDF]
Rheumatology and TherapyIntroduction Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had inadequate ...
Andrew Östör +13 more
doaj +2 more sources
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy [PDF]
Dermatology Practical & ConceptualIntroduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two ...
Federico Pirro +21 more
doaj +2 more sources
Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database [PDF]
Frontiers in PharmacologyBackgroundRisankizumab and guselkumab are two leading interleukin-23 (IL-23) inhibitors for treating immune-mediated inflammatory diseases. While effective, a direct comparison of their real-world safety profiles is lacking.
Shiyi Wang +7 more
doaj +2 more sources